Gene therapy involves the transfer of a gene of interest to a relevant cell type to cure a disease. In the context of primary immunodeficiency (PID), this means using a viral vector to deliver a specific transgene (corrective cDNA) to autologous haematopoietic stem and progenitor cells (HSCs), thereby allowing the development of a functional immune system.
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Further work demonstrated that accumulation of genetic lesions, rather than a single event, led to the development of leukaemia in these patients. However, the recognition of this mechanism led to the design of self-inactivating γRV and lentiviral vectors (SIN-γRV and SIN-LV), which did not contain harmful viral long terminal repeat (LTR) (see Glossary) sequences and instead incorporated alternative mammalian or endogenous promoters to drive transgene expression. Several of these vectors are now in Phase I/II clinical trials for all the above PIDs, and while they demonstrate efficacy comparable with that of early γRV trials, no adverse events related to clonal expansion have been reported [7] [8] [9] [10] . Nevertheless, these initial studies proved that gene therapy could offer significant clinical benefit and improve patient survival, even if the promise of this treatment was overshadowed by adverse events.
The purpose of this review is to highlight the results and clinical impact of more recent
Phase I/II trials in PIDs; further background is available in other reviews. We also discuss the results from preclinical studies that have been developing curative gene therapy for an expanding range of immune disorders, describing how the emergence of gene editing technologies brings forth the potential to change the face of gene therapy by improving both safety and efficacy through targeted gene correction. 
Treating SCIDs
Adenosine deaminase is an essential enzyme in the purine metabolism pathway and its deficiency leads to the accumulation of toxic metabolites. Thus, ADA-SCID is a multisystem disorder affecting not only the immune system, so patients may also manifest skeletal, neurological, and pulmonary symptoms. However, it is the severe immune deficiency that 5 causes the most significant clinical disease, with infants presenting with life-threatening infections due to a lack of T, B, and natural killer (NK) lymphocytes. Delivery of enzyme replacement therapy (ERT) with PEG-ADA can ameliorate the immune phenotype and allow systemic detoxification before a definitive procedure, but ERT alone is not considered a wholly effective long-term therapy [11] . ADA-SCID was the first PID to be treated with gene therapy, initially using autologous T lymphocytes and then HSCs with γRV vectors [12] [13] [14] [15] .
Over 40 patients with ADA-SCID have subsequently been treated with conventional γRV vectors since 2000, with 100% survival and 75% disease-free survival (meaning that they have not recommenced ERT or progressed to HSCT). The results of γRV-based trials undertaken in Milan, London, and the USA (UCLA/NIH) have been published and show persistence of gene-corrected cells, good immune reconstitution, and, importantly, metabolic detoxification [16] [17] [18] . Most patients enrolled in these studies received cytoreductive chemotherapy before infusion of gene-modified HSCs (busulfan 4 mg/kg or melphalan 140 mg/m 2 ), with PEG-ADA withdrawn before treatment to promote any survival advantage afforded by gene-corrected cells. As mentioned above, no severe adverse events related to insertional mutagenesis have been reported in any of these patients despite equivalent vector design and integration profiles similar to those seen in other trials in which they did occur. Although the specific reason for this is unclear, it is likely to represent a disease-specific phenomenon.
More recently, a SIN-LV construct was developed that contained codon-optimised ADA cDNA under the control of the elongation factor 1α short (EFS) promoter. This vector proved efficacious in preclinical studies [19] and entered clinical trials in 2012 in London and Los Angeles. The treatment protocol involves the harvest of autologous CD34 + cells from bone marrow (BM) or of mobilised peripheral blood stem cells (PBSCs). It is increasingly evident 6 that reinfusion of higher numbers of gene-corrected progenitor cells improves the outcome and harvest of mobilised PBSCs through leukapheresis and allows the collection of larger numbers of CD34 + cells. It is also clear that the use of reduced-intensity conditioning secures engraftment of gene-modified HSCs [20] and in these studies the patients received a single dose of busulfan (4-5 mg/kg). Preliminary results from the first 20 patients treated are promising [10] . The age of patients treated ranged from 5 months to 6. [20] . Of note, integration site analysis has shown a polyclonal pattern of vector insertion sites [20] . Thus, the safety and efficacy of HSC gene therapy for ADA-SCID has now been proved over several trials, allowing gene therapy to stand as an alternative treatment even for patients who have a matched unrelated donor available for transplantation, as this treatment is associated with less use of chemotherapy and no risk of graft-versus-host disease. Consequently, it is likely that ADA-SCID will become the first ex vivo gene therapy treatment to be commercially licensed. comparative study with haploidentical HSCT revealed superior rates and levels of reconstitution associated with autologous gene therapy [24] . This is noteworthy, as enhanced immune reconstitution may be important in the patient's early protection against infections. However, due to transactivation of proto-oncogenes (mainly LMO2 and CCND2), five of the treated patients developed T cell acute lymphoblastic leukaemia (T-ALL) as long as 6 years post-gene therapy [1, 2] . Four patients remain in remission following successful chemotherapy and one patient died [1, 2] .
Following the genotoxicity associated with this trial, the field focussed on improving the safety profile of the procedure through refinements in vector design. Figure 1 shows the evolution of safer vector configurations with progression from LTR-driven γRV vectors to SIN-γRV vectors and subsequently SIN-LV vectors, which are currently in clinical use. In 2010, parallel clinical trials for X-SCID using a SIN-γRV vector with IL2RG expression driven by the mammalian EFS promoter began in Europe and the USA, but again these were unconditioned procedures [7] . Preliminary results have been published for nine treated boys, suggesting an efficacy comparable with the γRV vector but with a significantly 'improved' integration profile (fewer insertions recovered close to proto-oncogenes) [7] . Currently, new trials are planned or under way where preparative chemotherapy is being used to potentially enhance humoral recovery to further improve patient outcome [25] .
Gene Therapy for Non-SCID Immunodeficiencies
Non-SCID PIDs present numerous challenges in the context of HSC gene therapy; these conditions tend to have wider variability in clinical features and less survival advantage for gene-corrected cells and more intense conditioning is therefore required to secure longterm engraftment.
WAS is an X-linked condition arising from mutations in the WAS gene and is characterised by microthrombocytopaenia, eczema, infections, and autoimmunity. Boys also have an increased risk of malignancy [26] . In a similar fashion to gene therapy for SCID, early trials involving γRV-mediated gene transfer have been superseded by the use of SIN-LV vectors, again in response to the development of haematological malignancies in treated patients [3, 4] . Genomic integrations were present in proto-oncogenes identified in other γRV trials, including LMO2, CCND2, and MDS1/EVI1. Six patients went on to develop T-ALL between 16 months and 5 years post-therapy and AML was described in three patients (one primary and two secondary) [3, 4] . 9 A SIN-LV vector containing a 1.6-kb fragment of the WAS promoter has subsequently been developed and has been used in clinical trials in Milan, London, Paris, and Boston since 2010
with the preliminary results published recently [8, 9] . All studies used a combination of busulfan and fludarabine preconditioning. Twenty-one patients in total have now been treated and preliminary results suggest stable engraftment of gene-modified cells and a substantial clinical benefit. Platelet counts, bleeding episodes, severe infections, autoimmunity, and eczema were improved in most patients [8, 9] . The highest levels of gene marking were achieved in lymphocytes, reflecting a survival advantage particularly for mature cells. In general, platelet recovery has been variable, perhaps reflecting suboptimal expression of the WAS protein in this lineage. However, higher cell doses have been associated with improved engraftment of gene-marked cells as well as partial resolution of thrombocytopaenia. In addition, there has been no evidence of genotoxicity at this relatively early time point and the results available so far are extremely promising [8, 9] .
CGD is caused by mutations affecting several proteins that comprise the NADPH oxidase complex, reducing the ability of phagocytes (particularly neutrophils) to kill bacterial and fungal pathogens. The most common mutations are found in the CYBB gene, which encodes the gp91phox protein, a key electron-transporting component of the NADPH oxidase complex. This form of CGD is inherited in an X-linked manner. Gene therapy trials to treat Xlinked CGD were initiated in the mid-1990s in the USA and utilised a γRV vector similar to that used in X-SCID trials. Five patients were enrolled and received no preconditioning before infusion of gene-corrected cells [27] . Although transient improvement in neutrophil function and clinical benefit was demonstrated, this was not sustained (but also not unexpected), as restoration of gp91phox protein expression does not confer a selective advantage. Subsequent trials undertaken at several centres worldwide have used non-10 myeloablative conditioning to improve engraftment and promote long-term clinical benefit using the same vector design [5, 6, [28] [29] [30] [31] . In several patients, neutrophil function improved temporarily with up to 25% gene-marked neutrophils in the periphery, but due to a lack of sustained HSC engraftment the presence of functional neutrophils did not persist [5, 6] . Four treated patients derived significant clinical benefit from gene therapy with persistently higher levels of functional neutrophils present in the blood [5, 6] . This effect was in fact supported by clonal expansions related to γRV-mediated transactivation of the oncogenes MECOM (MDS1/EVI1 complex locus) and PRDM1 (Blimp-1) [5, 6] . Furthermore, over time neutrophil function deteriorated and gp91phox protein expression was lost as a result of transgene silencing through methylation of the viral LTR [5, 6] . In Frankfurt, the two adult treated patients developed myelodysplasia and consequently died from complications [6] .
Two children treated in Zurich also developed mutagenic clonal expansions but received successful HSCT, one before developing frank myelodysplasia [31] .
In response to the high risk of genotoxicity in these studies, safer vectors have been designed for CGD, namely SIN-γRV [32] and SIN-LV [33, 34] . These vectors incorporate myeloid-specific promoter elements allowing high levels of gp91phox expression in terminally differentiated neutrophils while detargeting expression in HSCs to potentially reduce the risk of insertional toxicity. The vector currently under evaluation in multicentre trials is a SIN-LV configuration with a chimeric promoter formed from the myeloid-specific Cathepsin G and c-Fes regulatory elements [34] . This promoter element allows preferential expression in myeloid cell and differentiated granulocytes [34] .
Early-phase clinical trials using SIN-configuration vectors are under way in Europe and the USA ( Table 1 ). The range of inherited monogenic conditions treatable by HSC gene therapy is rapidly expanding and, although beyond the scope of this review, it is noteworthy that 11 clinical trials of SIN-LV vectors are either under way or planned for several other tractable conditions, including RAG1 and Artemis-SCID.
Preclinical Development of Lentiviral Gene Therapy for Inherited Immune Disorders
Given the encouraging results and clinical benefit seen in patients outlined above, gene therapy strategies are being developed for numerous other monogenic PIDs, several of which are nearing Phase I clinical trials. V(D)J recombination defects account for almost onethird of SCID cases and lead to a T − B − NK + phenotype due to an inability to generate T cell and B cell receptors, severely limiting lymphocyte development and the immune repertoire [35] . Causes include mutations in the recombination activation genes (RAG1 and RAG2) and the Artemis gene. These forms of SCID are an important target for clinical gene therapy, as the results following HSCT for these conditions can be poor. Artemis-SCID is a DNA repair defect and thus is associated with radiosensitivity and an increased risk of malignancy. This is highly relevant not only for HSCT but for the development of appropriate gene therapy protocols.
Correction of a murine model of Artemis-SCID has been achieved using a SIN-LV vector with transgene expression under the control of the internal phosphoglycerate kinase (PGK)
promoter [36, 37] . Stable immune recovery of both T and B cells, comparable with levels observed in wild-type animals, was demonstrated at low copy number (VCN ~1 copy/cell).
The effect of copy number has been particularly important for RAG1 gene therapy. RAG1-deficient mice receiving a SIN-LV vector displayed functional immune reconstitution but clinically relevant efficacy was achieved only with high VCN, suggesting that internal regulatory sequences are currently insufficient for this condition [38] . However, the requirement for such a high VCN does raise concerns around the increased risk of 12 insertional mutagenesis, which would be an important consideration in terms of clinical translation. Further work has shown that HSC transduction at lower VCN leads to partial T and B cell recovery with reduced thymic cellularity and this is associated with the production of autoreactive T cells similar to those seen in patients with hypomorphic RAG-SCID (Omenn's syndrome) [39] . A RAG2 −/− mouse model has also been corrected using a γRV and SIN-LV vector with a codon-optimised transgene to induce RAG2 expression [40, 41] . As opposed to weak cellular promoters where B cell reconstitution was impaired, this RAG2 expression, which was driven by a ubiquitous chromatin opening element (UCOE), was able to restore T and B cell development and function in the murine model [40] . This provides support for clinical development of this type of vector design.
The importance of promoter choice has been illustrated in a number of PID models where a fine balance exists between allowing sufficient levels of transgene expression to correct the phenotype and eliciting cell toxicity due to overexpression of a tightly regulated molecule.
Another PID example is leukocyte adhesion deficiency type 1 (LAD-1), which arises due to mutations in the leukocyte integrin CD18 and is characterised by severe bacterial infections.
Two patients were treated with a γRV construct in 1999 in the USA but no sustained benefit was reported [42] . SIN-LV vectors containing various promoters such as PGK and EFS, both ubiquitous and disease specific (CD18, CD11b), have been investigated in a canine model of the disease (CLAD) [43] [44] [45] . However, disease recovery was suboptimal using the human EFS and PGK promoters compared with the murine stem cell virus promoter (MSCV) or human CD11b or CD18 promoter [43] [44] [45] . Sustained disease amelioration has been described after long-term follow up of dogs receiving CD34 + progenitors transduced with a SIN-foamy virus (and MSCV promoter) with no vector-related adverse events [46] . Ongoing studies using a Nevertheless, the CD40L endogenous promoter can support an expression profile that recapitulates, to some extent, physiological CD40L protein levels. Thus, these results are highly relevant for the application of these promoters in the clinic [51, 52] .
Several PIDs in which the defect is limited to the lymphoid compartment, as in CD40L deficiency, immunodysregulation, polyendocrinopathy, enteropathy X-linked syndrome 14 (IPEX), and HLH, also lend themselves to corrective strategies employing transfer of autologous gene-corrected HSCs or T cells. Proof-of-concept studies for either a HSC or a T cell approach have been published or are under way for certain forms of familial haemophagocytic lymphohistiocytosis (FHL) (perforin deficiency [53] and Munc 13-4 deficiency, X-linked lymphoproliferative disease [54] , and IPEX) [55] . suggesting that long-term correction of the T cell compartment is possible [53] [54] [55] .
Targeted Gene Correction
The rapid development of gene editing technologies over the past decade has pushed to the an appropriate donor sequence [56] . Presently, the relatively low efficiency of repair by HR in HSCs limits the clinical application of this approach. However, the investigation of various delivery methods for the editing tools, donor DNA, and specific culture conditions may improve HSC-mediated clinical applications over time.
In the context of HIV infection or cancer, deleterious mutations in specific genes via ZFNs and TALENs are being tested in humans in ongoing studies in the USA and Europe [57] . This work has involved modifying patient T cells and although this approach would be transferable to some PIDs, correction of patient HSCs remains the ultimate aim. Successful correction of human haematopoietic progenitor cells has already been reported, which
represents an important step in realising the treatment of PID patients through genome editing [58] . To pursue improved treatments for X-SCID, Genovese et al. were able to target the integration of corrective cDNA into the IL2RG locus in patient CD34 + cells and demonstrate multilineage differentiation, as well as long-term immune reconstitution when transferring gene-corrected HSCs into NSG mice [58] . Using CGD as an example, patientderived induced pluripotent stem cells (iPSCs) have also been utilised as an in vitro model to demonstrate successful genetic correction by means of ZFNs [59] , TALENS [60] , and CRISPR/Cas9 [61] . Although the efficiency of genome editing is a limiting factor for progression of HSC-based therapy in the clinic, T cells appear to be more amenable to this technology, as has been shown through clinical studies in patients with HIV and cancer [57, 62] . As discussed above, specific PIDs may be treated by a gene-corrected T cell approach and therefore gene editing could be used in this setting. Studies using TALENs and CRISPR/Cas systems to correct CD40L deficiency and XLP are also under way. 16 Despite current challenges associated with these technologies (Figure 2 ), some of which primarily relate to low efficiency of correction and off-target effects, it is highly probable that, in the coming years, gene editing techniques will progress to clinical translation to treat severe PIDs.
Concluding Remarks
Somatic gene therapy of inherited immunodeficiency has in many ways led the way in the development of technologies that can now be applied to the treatment of a range of inherited disorders. The numbers of patients that have been successfully treated is approaching levels where this strategy can be considered as a frontline approach, in addition to more conventional allogeneic procedures. Efforts are now under way in several areas to develop commercial models that will enable much wider dissemination and adoption in health-care systems. New technologies, including gene editing in particular, offer the exciting promise of much more precise genetic correction or targeted gene addition but will have to tackle important issues related to safety, efficacy, and scalability before being widely applicable (see Outstanding Questions and Figure 2) . The future appears particularly bright for ex vivo gene therapy and the next decade will undoubtedly see similar approaches being applied to a much wider range of tractable haematological and metabolic diseases. In later vector designs, the transgene cDNA has sometimes been codon optimised (CO cDNA) to further improve gene expression. Cell (HSC) Gene Therapy. Developments in three main areas have the potential to improve both the safety and the efficacy of HSC gene therapy. Greater accessibility to treatment will allow more patients to be treated, thereby generating substantial data that can be used to further understand the effect of variables such as cell dose and levels of engraftment on outcome. This, along with the incorporation of technological advances -for example, those
